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GM-CSF (Csf-2) is a critical cytokine for the in vitro
generation of dendritic cells (DCs) and is thought to
control the development of inflammatory DCs and
resident CD103+ DCs in some tissues. Here we
showed that in contrast to the current understanding,
Csf-2 receptor acts in the steady state to promote the
survival and homeostasis of nonlymphoid tissue-
resident CD103+ and CD11b+ DCs. Absence of
Csf-2 receptor on lung DCs abrogated the induction
of CD8+ T cell immunity after immunization with
particulate antigens. In contrast, Csf-2 receptor
was dispensable for the differentiation and innate
function of inflammatory DCs during acute injuries.
Instead, inflammatory DCs required Csf-1 receptor
for their development. Thus, Csf-2 is important in
vaccine-induced CD8+ T cell immunity through the
regulation of nonlymphoid tissue DC homeostasis
rather than control of inflammatory DCs in vivo.
INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells
and key regulators of innate and adaptive immune responses.
Tissue-resident DCs refer to DCs other than plasmacytoid DCs
that populate the normal noninflamed tissues. In mice, tissue-
resident DCs consist of two phenotypically and developmentally
distinct subsets that include the CD8+CD103+ DCs and the
CD11b+ DC subsets (Hashimoto et al., 2011b; Heath and Car-
bone, 2009). The CD8+CD103+ DCs share a common origin,
phenotype, and function. They derive fromDC-restricted precur-
sors independent of monocytes (Bogunovic et al., 2009; Ginhoux
et al., 2009; Liu et al., 2009; Naik et al., 2007; Onai et al., 2007;Varol et al., 2009) and are dependent on Flt3 ligand (Flt3L) and
on the transcription factors Batf3, IRF8, and Id2 for their develop-
ment (Edelson et al., 2010; Ginhoux et al., 2009; Hashimoto et al.,
2011b; Hildner et al., 2008). Phenotypically, they lack the integrin
CD11b and themacrophagemarkers F4/80 and SIRPa (CD172a)
and they express the integrin CD103 in nonlymphoid tissues,
whereas in lymphoid organs they express the lymphoid marker
CD8 (Edelson et al., 2010; Ginhoux et al., 2009; Hashimoto
et al., 2011b; Hildner et al., 2008). In contrast, CD11b+ DCs
are more heterogeneous and include DCs that arise from
DC-restricted precursors in a Flt3L-dependent manner, but
also DCs that arise from circulating monocytes and macro-
phage-colony stimulating factor (M-CSF, Csf-1) receptor (Csf-
1r) do not require Batf3, Id2, and IRF8 for their development
(Edelson et al., 2010; Ginhoux et al., 2009; Hashimoto et al.,
2011b; Hildner et al., 2008). In addition to tissue-resident DCs,
tissue-draining lymph nodes (LNs) also contain nonlymphoid
tissue CD103+ DCs and CD11b+ DCs that have migrated from
the drained tissue, also called ‘‘tissue migratory cDCs’’ (Ran-
dolph et al., 2005).
In the inflamed setting, however, a distinct population of
DCs is transiently formed and accumulates in injured tissues
in response to microbial or inflammatory stimuli and disappears
once the inflammation resolves. Inflammatory DCs are thought
to derive from circulating Ly6Chi monocytes and are best
characterized by the expression of Ly6C, high expression of
the integrin CD11b, and intermediate levels of the integrin
CD11c (Domı´nguez and Ardavı´n, 2010). One of the best exam-
ples of inflammatory DCs are TNF-a- and iNOS-producing DCs
(TipDCs) (Serbina et al., 2003) that accumulate in the spleen of
mice infected with Listeria monocytogenes (L. monocytogenes).
TipDCs and inflammatory DCs have also been described in
other inflammatory diseases (Domı´nguez and Ardavı´n, 2010)
and participate in the control of infections (Aldridge et al.,
2009; Leo´n and Ardavı´n, 2008; Rydstro¨m and Wick, 2007; Ser-
bina et al., 2003).Immunity 36, 1031–1046, June 29, 2012 ª2012 Elsevier Inc. 1031
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Figure 1. Csf-2r Is Highly Expressed on Nonlymphoid Tissue-Resident DCs in the Steady State
(A) Csf2rb, Csf2ra, Il3ra, and Il5ra expression profile of purified tissue DC populations was analyzed with Affymetrix gene chip arrays. Graphs show the relative
mRNA expression of purified spleen-resident CD8+ and CD11b+ DCs, nonlymphoid tissue-resident CD103+ and CD11b+ DC subsets, migratory CD103+ and
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Immunity
GM-CSF Controls Tissue DC HomeostasisGranulocyte-macrophage colony stimulating factor (GM-CSF,
Csf-2) is a hematopoietic growth factor that controls the differ-
entiation of the myeloid lineage (Metcalf, 2008). In addition to
its effects on hematopoietic progenitors, Csf-2 can also modu-
late the function of mature hematopoietic cells (Metcalf, 2008).
For example, in the lung, Csf-2 is essential to promote surfactant
clearance by alveolar macrophages, and deletion of Csf-2
(Dranoff et al., 1994; Stanley et al., 1994) or Csf-2 receptor
(Csf-2r) (Nishinakamura et al., 1995) leads to alveolar proteinosis
because of the accumulation of lipoproteinaceous material in
lung alveoli (Trapnell et al., 2003). The pivotal role for Csf-2 in
DC development was first identified by in vitro studies. In these
studies, Csf-2 was required to promote the differentiation of
mouse and human hematopoietic progenitors and human
circulating monocytes into cells that resemble mouse splenic
DCs (Caux et al., 1996; Inaba et al., 1992; Sallusto and Lanza-
vecchia, 1994). Csf-2 remains to date a key cytokine to generate
DC-based vaccines for clinical use (Banchereau and Palucka,
2005). Therefore, it came as a surprise that mice lacking Csf-2
or its receptor displayed only minor impairment in the develop-
ment of spleen and lymph node (LN) DCs (Vremec et al.,
1997). Subsequent studies showing that Csf-2 is increased in
the serum of inflamed mice, together with data suggesting that
adoptively transferred monocytes differentiate into DCs mainly
in the inflamed spleen, led to the current dogma that Csf-2
controls monocyte-derived DC differentiation in vivo (Naik
et al., 2006; Shortman and Naik, 2007). Results from our labora-
tory revealed that absence of Csf-2r impaired the development
of a specific lamina propria DC population (Bogunovic et al.,
2009). A subsequent study revealed that Csf-2 also controls
the development of dermal CD103+ DCs (King et al., 2010),
prompting us to revisit the role of Csf-2 and its receptor in the
control of the DC lineage.
Ourdata revealed thatCsf-2r signaling is required for thedevel-
opment of nonlymphoid tissue-resident DCs in the steady state
and for the induction of CD8+ T cell immunity against particulate
antigens. We also found that in contrast to the current under-
standing, inflammatory DCs that accumulate in injured tissues
develop independently of Csf-2r signaling and identified Csf-1r
as a key molecule for the development of inflammatory DCs.
RESULTS
DCs Have High Csf-2r Expression in the Steady State
To determine the role of Csf-2 in DC development in the steady
state, we first examined the expression profile of the Csf-2r
among lymphoid and nonlymphoid tissue DCs in normal nonin-CD11b+ DCs in tissue-draining LNs, and epidermal and migratory LCs in skin-dra
SEM (nR 3). Spl, spleen; SLN, skin-draining LN; SI, small intestine.
(B) Histograms depict the expression of Csf-2rb on DCs isolated from lymphoid
T cells and neutrophils (SSChiCD11b+Gr1+) isolated from the spleen of WT mice
(C) Histograms depict the expression of IL-3ra and IL-5ra on DCs isolated from the
IL-3ra (CD123) and IL-5ra (CD125) antibody.
(D and E) WT mice, Csf2rb/Csf2rb2/ mice (D), and Csf2/ mice (E) were an
show the absolute cell numbers of DCs in the lung (D and E: n = 6) and in the d
lung-draining LNs (D and E: n = 4), and mesenteric (mes.) LNs (E: n = 3), and DCs
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, unpaired).
See also Figure S2.flamed conditions. Csf-2 binds specifically to the Csf-2r, a
heterodimer composed of a cytokine-specific a chain (Csf-
2ra, Csf2ra) and a common signaling b chain (bc, Csf-2rb,
Csf2rb) that is shared with the receptors for IL-3 (IL-3r) and IL-
5 (IL-5r) (Martinez-Moczygemba and Huston, 2003). In mice,
IL-3r also possesses a second b subunit called Csf-2rb2
(Csf2rb2), which together with IL-3r-specific a chain is sufficient
to drive IL-3 signaling in the absence of Csf-2rb (Robb et al.,
1995).
Expression array analysis of tissue-resident and migratory
DC subsets in nonlymphoid and lymphoid tissues revealed that
all DC subsets expressed high amounts of Csf2ra and Csf2rb
transcript (Figure 1A; Figure S1A available online). By using
flow cytometry analysis, we confirmed that Csf-2rb was also
highly expressed on lymphoid and nonlymphoid tissue DCs
(Figure 1B). Splenic CD4+ and CD8+ T cells that lack Csf-2rb
(Morrissey et al., 1987; Sonderegger et al., 2008) and neutrophils
that express Csf-2rb were used as controls. In contrast, in the
steady state, nonlymphoid tissue DCs expressed low IL-3r-
and IL-5r-specific a chains (IL-3ra and IL-5ra, respectively)
(Figures 1A and 1C).
Csf-2r Controls Nonlymphoid Tissue DC Homeostasis
In Vivo
To further establish the role of Csf-2 in DC development in the
steady state, we examined whether lymphoid tissue CD8+ and
CD11b+ and nonlymphoid tissue CD103+ and CD11b+ DC pop-
ulations were affected in Csf-2r-deficient (Csf2rb/Csf2rb2/)
mice that lack the common b subunit (Csf2rb) and the IL-3r
unique b subunit (Csf2rb2). We found that Csf2rb/Csf2rb2/
mice have much lower numbers of CD103+ DCs in the lung,
lung-draining LNs, and lamina propria compared to wild-type
(WT) mice (Figures 1D and S1). Consistent with prior studies
(King et al., 2010), CD103+ DCs were also strongly reduced
in the dermis and skin-draining LNs of Csf2rb/Csf2rb2/
mice, whereas spleen, LN-resident DCs, and epidermal Langer-
hans cells (LCs) developed normally in the absence of Csf-2r
(Bogunovic et al., 2009; Vremec et al., 1997; data not shown).
CD11b+ DCs were not affected in Csf2rb/Csf2rb2/ mice
except in the lamina propria, where CD11b+CD103+ DCs were
reduced (Figure 1D).
Csf-2 Controls Nonlymphoid Tissue DC Homeostasis
In Vivo
As shown above, tissue DCs express no IL-5ra (Figures 1A–1C).
Therefore, DC defects observed in Csf2rb/Csf2rb2/ mice
are probably independent of IL-5, but combined defects inining LNs isolated as described in Figure S1. Bar graphs represent the mean ±
and nonlymphoid tissues and CD4+ (CD4+MHCII) and CD8+ (CD8+MHCII)
. Dashed gray line, isotype control; solid black line, anti-Csf-2rb (CD131).
spleen and lung ofWTmice. Dashed gray line, isotype control; solid black line,
alyzed for the presence of the DC subsets as described in Figure S1A. Graphs
ermis (D and E: n R 7), migratory DCs in skin-draining LNs (D and E: n = 4),
in the lamina propria (D: n = 3, E: n = 4). Bar graphs represent the mean ± SEM.
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Immunity
GM-CSF Controls Tissue DC HomeostasisCsf-2 and IL-3 signaling could potentially contribute to the DC
phenotype observed in these mice. To examine the contribution
of Csf-2 and IL-3 to DC homeostasis, we analyzed tissue
DCs in Csf2rb/ mice, which have intact Csf-2rb2 chain and
can therefore respond to IL-3 stimulation (Robb et al., 1995).
Nonlymphoid tissue DCs were similarly reduced in Csf2rb/
mice compared to Csf2rb/Csf2rb2/ mice, establishing that
IL-3 is dispensable for DC homeostasis in vivo (Figure S1B).
Similar to Csf2rb/ mice, Csf2/ mice had a strong reduction
of lung- and skin-resident CD103+ DCs as well as migratory
CD103+ DCs in the lung-draining and skin-draining LNs
(Figure 1E) and also displayed reduced numbers of lung
CD11b+ DCs, dermal CD11b+ DCs, and CD103+CD11b+ DCs
in the lamina propria and mesenteric LNs, establishing that
Csf-2 is required to maintain DC homeostasis in nonlymphoid
tissues in vivo. To assess the source of Csf-2 required to support
DC homeostasis, we generated WT/Csf2/ bone marrow
(BM) chimeric mice as well as Csf2//WT BM chimeras.
We found that tissue CD103+ and CD11b+ DCs were reduced
both inWT/Csf2/ andCsf2//WTBM chimeric mice, sug-
gesting that Csf-2 produced by radiosensitive hematopoietic
cells and radio-resistant cells contributes to DC homeostasis
(Figure S2).
Csf-2 regulates CD103 expression on DCs (Zhan et al., 2011),
which prompted us to determine whether CD103+ DC defects
observed inCsf2rb/Csf2rb2/mice reflected a true reduction
of CD103+ DCs or only a modulation of CD103 expression by
this cell population. Therefore, we assessed the reduction of
DCs using surrogate markers of CD103+ DCs, such as the
marker CD24 and lack of expression of CD11b (Figure S1).
Importantly, we found that nonlymphoid tissue CD24+CD11b
DCs were also reduced in Csf2/ mice (Figure 1E) and
Csf2rb/ mice (Figure S1B), suggesting that absence of Csf-
2r affected not only CD103 expression but also CD103+ DC
homeostasis in vivo.
Csf-2r Plays a Cell-Intrinsic Role in DC Homeostasis
To examine whether Csf-2r regulation of tissue DC homeostasis
was cell intrinsic, we generated mixed BM chimeric mice with
a 1:1 mixture of CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/ or
CD45.1+ WT:CD45.2+ WT BM cells. Two months after recon-
stitution, we found that CD45.2+Csf2rb/Csf2rb2/CD103+
DCs were strongly reduced in the lung, skin, liver, and kidney
in comparison to WT CD103+ DCs in the same animal and
compared to CD103+ DCs in WT BM chimeric mice (Figures
2A–2D). Importantly, CD45.2+Csf2rb/Csf2rb2/CD11b+ DCs
were also reduced in the lung, lung-draining LN, dermis, skin-
draining LN, lamina propria, and mesenteric LN, suggesting
that Csf-2r also regulates cell intrinsically the homeostasis of
the CD11b
+
DC subset in vivo.
Consistent with our finding in mutant mice, Csf2rb/
Csf2rb2/CD24+CD11b DCs in mixed BM chimeric animals
were strongly reduced in the lung and lung-draining LN
compared to WT DCs, and CD103 expression was further
reduced on the remaining Csf2rb/Csf2rb2/CD24+CD11b
DCs (Figure S3C). The numbers of CD24+Csf2rb/Csf2rb2/
kidney DCs were only slightly decreased although they ex-
hibited a complete downregulation of CD103 (Figure 2D). These
data indicate that although Csf-2 ubiquitously regulates the1034 Immunity 36, 1031–1046, June 29, 2012 ª2012 Elsevier Inc.expression of CD103, the impact of Csf-2 on DC homeostasis
is tissue specific. Consistent with our findings in Csf2rb/
Csf2rb2/ mice, lymphoid tissue-resident DCs were not
affected in mixed BM chimeric mice (Figure S3A). In addition,
Csf2rb/ BM chimeric mice cells displayed similar tissue
DC defects (Figure 2E) as compared to Csf2rb/Csf2rb2/
chimeric mice, indicating again that DC deficiency resulted
from abrogated Csf-2 signaling rather than disrupted IL-3
signaling. Thus, Csf-2 produced by hematopoietic and stromal
cells drives Csf-2r cell-intrinsic control of nonlymphoid tissue-
resident CD103+ and CD11b+ DC homeostasis in vivo.
Csf-2r Does Not Control the Commitment of
Hematopoietic Progenitors into the DC Lineage In Vivo
Recent studies established that the earliest myeloid commit-
ment to the DC lineage occurs at the macrophage and DC
precursor (MDP) stage. MDP gives rise to monocytes and to
the common DC precursor (CDP) that produces exclusively
plasmacytoid DCs and preDCs, a circulating DC-restricted
progenitor that gives rise exclusively to DCs in both lymphoid
and nonlymphoid tissue DCs (Bogunovic et al., 2009; Fogg
et al., 2006; Ginhoux et al., 2009; Liu et al., 2009; Naik et al.,
2007; Onai et al., 2007; Varol et al., 2007; Waskow et al.,
2008).
To examine whether Csf-2 controls DC homeostasis in vivo
through its ability to control DC progenitor commitment, we
analyzed the expression of Csf-2rb, IL-3ra, and IL-5ra on
MDPs, CDPs, and preDCs at the mRNA and protein levels
by gene expression arrays and flow cytometry (Figures 3A
and 3B). Bone marrow MDPs and CDPs and preDCs expressed
Csf-2rb and IL-3ra but not IL-5ra, whereas preDCs in the
spleen expressed Csf-2rb but not IL-3ra and IL-5ra.
Absence of Csf-2rb and Csf-2rb2 did not affect the develop-
ment of MDPs, CDPs, and preDCs in mixed BM chimeric mice
(Figures 3C–3E), suggesting that the DC deficiency observed in
Csf2rb/Csf2rb2/ mice does not stem from a defect at the
precursor level but rather results from either impaired differenti-
ation or survival of mature DCs in nonlymphoid tissues.
Csf-2r Controls DC Survival in Nonlymphoid Tissues
Consistent with the hypothesis that Csf-2 acts on DCs locally in
nonlymphoid tissues, we found that Csf-2 expression was much
higher in nonlymphoid tissues in comparison to the spleen or
sera of naive WT mice (Figure 4A). To address whether Csf-2
plays a prosurvival role on tissue DCs, we cultured purified total
splenic DCs and CD103+ lung DCs overnight in the presence or
absence of Csf-2 and measured the activation of Caspase-3
(cleaved Caspase-3), which is indicative of cellular apoptosis.
Csf-2 addition to the culture medium resulted in reduced
active Caspase-3 by DCs together with increased absolute cell
numbers (Figures 4B and 4C), indicating that Csf-2 promoted
DC survival in vitro.
To further explore the prosurvival role of Csf-2 in vivo, we
analyzed WT and Csf2rb/Csf2rb2/ DCs isolated from the
lung of mixed BM chimeric animals for survival defects. First,
we labeled Csf2rb/Csf2rb2/ and WT DCs with Mitogreen
to assess mitochondrial network integrity via live cell fluorescent
microscopy. In parallel to promoting Caspase activation, mito-
chondria undergo marked fission as a result of apoptosis (Riedl
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Figure 2. Csf-2r Controls the Development of Nonlymphoid Tissue DCs
Mixed BM chimeras (CD45.1+ WT:CD45.2+ WT and CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/ (A–D), CD45.1+ WT:CD45.2+Csf2rb/ (E)) were analyzed for the
presence of CD45.1+ and CD45.2+ DCs. Dot plots show the percentage of CD45.1+ WT and CD45.2+Csf2rb/Csf2rb2/ nonlymphoid tissue-resident DCs
and LN-migratory DCs as described in Figure S1A. Bar graphs display the percentage ± SEM of CD45.2+ WT and CD45.2+Csf2rb/Csf2rb2/ DCs (A–D) or
CD45.2+Csf2rb/ DCs (E). (A)–(D): Lung and lung-draining LNs, n = 6; skin-draining LNs, n = 7; dermis, n = 9; lamina propria and mesenteric LNs, n = 4; liver,
n = 10; kidney, n = 4. (E): For all tissues, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, unpaired).
See also Figure S3.
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Figure 3. Csf-2r Does Not Control the Differentiation of DC-Restricted Precursors in the Bone Marrow
(A) Csf2rb, Csf2rb2, Csf2ra, Il3ra, Il5ra, Csf1r, and Flt3 expression profile of purified precursor populations (CDPs and MDPs) from the BM of WT mice was
analyzed with Affymetrix gene chip arrays. Graphs show the relative mRNA expression as the mean ± SEM (nR 3).
(B) Histograms depict the expression of Csf-2rb, IL-3ra, and IL-5ra on MDPs, CDPs, and preDCs isolated from the BM and preDCs isolated from the spleen.
Dashed gray line, isotype control; solid black line, antibodies against Csf-2rb, IL-3ra, and IL-5ra.
(C–E) Dot plots (C and D) depict the gating strategy to measure MDPs, CDPs (C), and preDCs (D) in the BM of mixed BM chimeras (CD45.1+ WT:CD45.2+ WT or
CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/). Bar graphs (E) show the percentage ± SEM of CD45.2+ circulating Ly6Chi monocytes and BM preDCs, MDPs, and
CDPs in mixed BM chimeric mice (n = 4).
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Figure 4. Csf2rb–/–Csf2rb2–/– Mice Cannot Mount
CD8+ T Cell Immunity upon Intratracheal Immuni-
zation with OVA Beads and Poly(I:C)
(A) Sera, lymphoid, and nonlymphoid tissues derived from
naive WT mice were analyzed for Csf-2 levels by ELISA.
Bars represent the mean ± SEM (n = 5).
(B and C) Splenic DCs (B) and lung CD103+ DCs (C) were
isolated from WT animals and cultured for 24 hr with
or without Csf-2. Plots show the percentage of active
Caspase-3+ DCs and the total cell number of viable DCs
(nR 2).
(D) CD103+ andCD11b+ DCswere sorted from the lungs of
CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/ BM chimeric
mice and stained with Mitogreen. Images show Mito-
green-stainedDCs. Scale bar represents 10 mm. Bar graph
depicts the percentage of DCs with fragmented mito-
chondria (nR 100 cells).
(E and F) WT and Csf2rb/Csf2rb2/ mice (E) and WT
and Csf2rb/Csf2rb2/ BM chimeric mice (WT/WT
and Csf2rb//WT) (F) were immunized i.t. with OVA-
coated latex beads mixed with poly(I:C) (OVA/PIC) or
left untreated. 7 days after immunization, lungs and
lung-draining LNs were analyzed for the presence of
OVA-specific CD8+ T cells via H2Kb/SIINFEKL-specific
pentamers. Nonimmunized (not imm.) mice were used
as controls. Plots represent the percentage and total
cell number of OVA-specific CD8+ T cells (gated on
B220–CD3+CD8+ cells) ± SEM (n = 3).
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test,
unpaired). See also Figures S4 and S5.
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GM-CSF Controls Tissue DC Homeostasisand Salvesen, 2007; Youle and Karbowski, 2005) and therefore
fragmentation of the mitochondrial network provides an excel-
lent measure of survival defects (Karbowski et al., 2002;Immunity 36, 10Martinou and Youle, 2011). We found that
the majority of mitochondria displayed a
fragmented phenotype with occasional swell-
ing and perinuclear localization in Csf2rb/
Csf2rb2/ DCs whereas the mitochondrial
membrane appeared unaffected in WT DCs
isolated from the lung of the same animal
(Figure 4D).
WT and Csf2rb/Csf2rb2/ DCs isolated
from mixed BM chimeras were also stained
with cleaved Caspase-3 antibody. Consistent
with the Mitogreen data, we found an in-
creased number of cleaved Caspase-3+ DCs
among Csf2rb/Csf2rb2/ DCs compared
to WT DCs (Figure S4A), strongly suggesting
that Csf-2r plays a key prosurvival role in
nonlymphoid tissue DCs in vivo. To directly
probe the prosurvival role of Csf-2 in
DCs in vivo, we measured the number
of Annexin-V+ apoptotic DCs among the
DCs that populate the lung and intestine of
Csf2/ and WT mice. We found a signifi-
cantly higher number of Annexin-V+DAPI
DCs in the lung of Csf2/ mice and in the
small intestine of Csf2rb/Csf2rb2/ mice
compared to WT mice (Figures S4B–S4D).Altogether, these results strongly establish the key role played
by Csf-2 and Csf-2r in promoting DC survival in nonlymphoid
tissues in vivo.31–1046, June 29, 2012 ª2012 Elsevier Inc. 1037
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Figure 5. Inflammatory DCs Develop Independently of Csf-2r Signaling
(A) WT mice were inoculated i.n. with PR8 influenza virus. Histograms depict phenotypic analysis of inflammatory DCs that accumulate in the lungs on day 3
postinfection. Dashed gray line, isotype; solid black line, markers as indicated above the histograms.
(B) Graphs display Csf2rb, Csf2ra, Flt3, and Csf1r relative mRNA expression in naive WT Ly6Chi blood monocytes, lung CD11b+ and CD103+ DCs isolated from
naive WT mice, and inflammatory DCs (infl. DCs) isolated from the lungs of influenza virus-infected WT mice.
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Immunity
GM-CSF Controls Tissue DC HomeostasisCsf2rb–/–Csf2rb2–/– Mice Cannot Mount Efficient
Antigen-Specific CD8+ T Cell Immunity upon
Immunization with Particulate Antigens In Vivo
To determine whether the defect in nonlymphoid tissue DC
development observed in Csf2rb/Csf2rb2/ mice would
affect the cross-priming of antigen-specific CD8+ T cells upon
immunization with particulate antigens, WT and Csf2rb/
Csf2rb2/ mice were injected intratracheally (i.t.) with the
adjuvant poly(I:C) together with latex beads coated with the
model antigen ovalbumin (OVA) (Jakubzick et al., 2008). Seven
days after immunization, we found that Csf2rb/Csf2rb2/
mice were unable to mount OVA-specific CD8+ T cell
immunity compared to WT mice (Figure 4E). However, because
Csf2rb/Csf2rb2/mice also develop lung alveolar proteinosis
secondary to defects in surfactant catabolism by alveolar
macrophages (Nishinakamura et al., 1995) that may compromise
T cell immune responses, we examined whether similar T cell
priming defects also arise in Csf2rb/Csf2rb2/ BM chimeric
mice that do not develop proteinosis, Strikingly, whereas
WT BM chimeric mice mounted a robust OVA-specific CD8+
T cell response, Csf2rb/Csf2rb2/ BM chimeric mice were
unable to mount OVA-specific CD8+ T cell immunity upon
i.t. immunization with OVA-coated latex beads and poly(I:C)
(Figure 4F). Defects in CD8+ T cells priming observed in
Csf2rb/Csf2rb2/ BM chimeric mice were probably due
to defective lung migratory CD103+CD8 DCs because lung
CD103+CD8 DCs (Figure S5A) and lung migratory CD103+
CD8 DCs were the main drivers of OT-I T cell proliferation
in WT mice (Figure S5B). Because Csf-2r is expressed by
DCs and not by T cells (Figure 1B; Morrissey et al., 1987;
Sonderegger et al., 2008), these results suggest that Csf-2r
controls the cross-priming of antigen-specific CD8+ T cells to
particulate antigens through its role on nonlymphoid tissue
migratory DCs.
Csf-2 Is Not Required for the Generation of Monocyte-
Derived DCs in the Acute Inflamed State
Csf-2 is thought to control the differentiation of inflammatory
DCs that accumulate in injured tissues (Shortman and Naik,
2007). To examine the regulation of inflammatory DC develop-
ment, we used several distinct tissue infection and acute inflam-
matory models including intranasal (i.n.) infection with influenza
A virus or Streptococcus pneumoniae (S. pneumoniae), oral
Salmonella Typhimurium (S. Typhimurium) infection, systemic
Listeria monocytogenes (L. monocytogenes) infection, or sys-
temic lipopolysaccharide (LPS) injection. Inflammatory DCs
that accumulated in influenza virus-infected lungs expressed
MHCII, CD11c, CD11b, Ly6C, and Mac-3 (Figure 5A) as previ-(C–E) Mixed BM chimeras (CD45.1+ WT:CD45.2+ WT or CD45.1+ WT:CD45.2+
inflammation stimuli. Dot plots show the percentage of CD45.1+ WT, CD45.2
(DAPI–CD11c+MHCII+CD11b+Ly6C+). Bar graphs display the percentage of CD
circulating CD45.2+ WT or Csf2rb/Csf2rb2/Ly6Chi monocytes are shown.
(C) Mice were inoculated i.n. with influenza virus (n = 3) or S. pneumoniae (n = 4)
(D) Mice were injected with LPS i.v. and lungs and spleens were analyzed 24 hr
(E) Mice were inoculated orally with S. Tymphimurium and lamina propria cells w
(F) Naive CD45.1+CD45.2+ F1 recipient mice were infected i.n. with influenza viru
Csf2rb2/Ly6Chi monocytes. Dot plots display the percentage of CD45.1+
(CD11c+MHCII+CD11b+Ly6C+) in the lungs and lung-draining LNs on day 3 after
See also Figure S6.ously described (Serbina et al., 2003). Lung inflammatory DCs
also expressed CD172a (Sirpa), F4/80, and CD24 (Figure 5A)
as well as Csf-2r, but surprisingly they expressed higher Csf-1r
levels and much lower Flt3 levels compared to lung tissue-
resident DCs (Figure 5B).
To examine whether the development and function of inflam-
matory DCs was dependent on Csf-2r signaling, we analyzed
the differentiation of inflammatory DCs in WT:Csf2rb/
Csf2rb2/ mixed BM chimeric mice in inflamed tissues
a few days after infection. Strikingly, a similar number of
Csf2rb/Csf2rb2/ and WT DCs accumulated in influenza
virus-infected lungs, S. pneumonia lungs (Figure 5C), LPS-
exposed lungs and spleens (Figure 5D), and S. Typhimurium-
infected lamina propria (Figure 5E). These results establish
that blood-derived DCs can accumulate in acute inflamed
tissues in the absence of Csf-2r signaling. Csf-2 also plays a
pivotal role for the development of experimental autoimmune
encephalomyelitis (EAE) (Codarri et al., 2011). However, consis-
tent with our findings in microbial-induced injury models,
similar numbers of Csf2rb/ and WT inflammatory DCs were
present in the CNS of mixed WT:Csf2rb/ BM chimeras during
the peak of disease in EAE mice (Figure S6).
To further assess whether monocytes differentiate into DCs in
the absence of Csf-2r signaling, we transferred a 1:1 mixture
of CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/ monocytes into
CD45.1+CD45.2+ F1 recipient mice 1 day after the recipient
mice were infected i.n. with influenza virus. Two days after
monocyte transfer, we measured the numbers of CD45.1+ WT
and CD45.2+Csf2rb/Csf2rb2/ monocyte-derived DCs in
influenza virus-infected lungs and lung-draining LNs of F1 recip-
ient animals (Figure 5F). We found that Csf2rb/Csf2rb2/
monocytes differentiate as efficiently as WT monocytes into
inflammatory DCs in injured tissues (Figure 5F), suggesting that
Csf-2r signaling does not control the differentiation of inflamma-
tory monocyte-derived DCs in vivo.
Csf2rb–/–Csf2rb2–/– Inflammatory DCs Have Normal
Innate Immune Function
One of the hallmarks of inflammatory DCs is their ability to
secrete TNF-a and/or iNOS (TipDCs), two molecules that
control antimicrobial host defense (Serbina et al., 2008). To
examine whether Csf2rb/Csf2rb2/ DCs were functionally
impaired compared to WT DCs, we measured TNF-a and iNOS
production of inflammatory Csf2rb/Csf2rb2/ and WT DCs
isolated from influenza virus-infected lungs, S. pneumonia-
infected lungs, and LPS-exposed lungs of mixed BM chi-
meric mice generated as described above. We found that
Csf2rb/Csf2rb2/ inflammatory DCs were as potent as WTCsf2rb/Csf2rb2/) were either left untreated or submitted to infections or
+Csf2rb/Csf2rb2/, or CD45.2+ WT DCs among total inflammatory DCs
45.2+ inflammatory DCs of pooled experiments. As a reference population,
and lungs were isolated 3 days later.
later (n = 3).
ere analyzed 4 days later (nR 3).
s 24 hr prior to i.v. injection of a 1:1 mixture of CD45.1+ WT:CD45.2+Csf2rb/
WT or CD45.2+Csf2rb/Csf2rb2/ monocyte-derived inflammatory DCs
transfer. One representative of two independent experiments is shown.
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Figure 6. Csf2rb–/–Csf2rb2–/– Inflammatory DCs
Can Efficiently Control Initial L. monocytogenes
Burden
(A) CD45.1+ WT:CD45.2+Csf2rb/Csf2rb2/ BM
chimeras were infected i.n. with influenza virus (n = 3)
or S. pneumoniae (n = 4) or injected with LPS i.v. (n = 3)
as described in Figure 5. Graph and dot plots show
the percentage of iNOS and TNF-a expression among
CD45.1+ WT or CD45.2+Csf2rb/Csf2rb2/ inflamma-
tory DCs (CD11c+MHCII+CD11b+Ly6C+) isolated from the
infected lungs.
(B–D) WT, Csf2rb–/–Csf2rb2/, and Ccr2–/– mice were
inoculated i.p. with L. monocytogenes.
(B) Absolute cell number of inflammatory DCs gated on
total DCs on day 3 postimmunization ± SEM (n = 4).
(C) Dot plots display the percentage of inflammatory DCs
gated on total DCs (CD11c+MCHII+) and the percentage of
inflammatory DCs expressing iNOS in the spleens of
WT, Csf2rb–/–Csf2rb2/, and Ccr2–/– mice on day 3 after
infection.
(D) Bar graph shows L. monocytogenes colony forming
units (CFU) in the spleens and livers ± SEM (n = 4) on day 3
after infection. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s
t test, unpaired).
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GM-CSF Controls Tissue DC Homeostasisinflammatory DCs at producing TNF-a and iNOS in inflamed
tissues (Figure 6A).
TipDCs have been shown to be most critical for the induction
of early innate immune defense against L. monocytogenes,
and Ccr2/ mice that lack TipDCs die during the first few
days after infection secondary to uncontrollable systemic
L. monocytogenes spread (Kurihara et al., 1997). To examine
whether the function of Csf2rb/Csf2rb2/ TipDCs was
compromised, we compared the ability of WT and Csf2rb/
Csf2rb2/ DCs to produce iNOS and to control bacterial
burden upon systemic L. monocytogenes infection. Ccr2/
mice were used as controls (Serbina et al., 2003). We found
that a similar number of Csf2rb/Csf2rb2/ and WT TipDCs
accumulated in the spleens of L. monocytogenes-infected
animals (Figure 6B). Csf2rb/Csf2rb2/ TipDCs in the spleens
of infected animals were as efficient as WT TipDCs at1040 Immunity 36, 1031–1046, June 29, 2012 ª2012 Elsevier Inc.producing iNOS (Figures 6B and 6C) and
Csf2rb/Csf2rb2/ mice were as efficient as
WT mice at controlling the L. monocytogenes
bacterial load in the spleen and liver during the
first days of infection, which was consistent
with the presence of TipDCs in these tissues
(Figures 6C and 6D). In agreement with other
reports, Ccr2/mice had a much higher bacte-
rial burden in the spleen and liver. These results
establish that TipDCs develop and function
in vivo independently of Csf-2r signaling.
Csf-1r Controls the Differentiation of
Inflammatory DCs
Csf-1 and its receptor (Csf-1r) is the primary
regulator of the mononuclear phagocytic
lineage. A null mutation of Csf-1r alters normal
macrophage development (including osteoclast
development leading to severe osteopetrosis)(Dai et al., 2002) and abrogates microglia development (Ginhoux
et al., 2010) and the development of epidermal LCs (Ginhoux
et al., 2006). Interestingly, we found that Csf-1r was expressed
at high levels on inflammatory DCs (Figures 5B and 7A) and
that Csf-1 was strongly increased in inflamed tissues (Figure 7B).
These results prompted us to revisit the role of Csf-1r in the
differentiation of monocyte-derived DCs in vivo.
We used two separate models to interfere with Csf-1r
signaling in inflamed mice. First, we crossed Csf-1r-floxed
(Csf1rfl/fl) mice with tamoxifen-inducible Rosa26CreER (Cre+)
mice. Administration of tamoxifen to these mice leads to the
excision of the Csf1r-floxed sequence resulting in a null allele
(Li et al., 2006).
Interestingly, we found that tamoxifen injection eliminated
Ly6Clo circulating monocytes (Figure 7C) but did not affect the
development of spleen- and LN-resident DCs and circulating
Immunity
GM-CSF Controls Tissue DC HomeostasisLy6Chi monocytes in uninfected spleens (Figures S7A and S7B)
nor did it affect the accumulation of Ly6Chi monocytes in LPS-
injured spleens (Figures 7D and S7B). In contrast, the number
of inflammatory DCs that accumulated in LPS-treated spleens
of Cre+ 3 Csf1rfl/fl tamoxifen-treated mice were reduced
compared to control animals (Figures 7D and S7B). Similar
results were obtained in influenza-infected mice (Figure 7G).
In a second model, we used a blocking monoclonal antibody
to Csf-1r (AFS98) prior to treating the mice with LPS (Sudo
et al., 1995). Consistent with the results obtained in Csf1rfl/fl
mice, administration of Csf-1r antibody in LPS-treated mice
strongly reduced Ly6Clo monocytes without affecting the
number of circulating Ly6Chi monocytes as previously shown
(Figure 7E; Hashimoto et al., 2011a; MacDonald et al., 2010).
Administration of Csf-1r antibody did not affect the accumulation
of circulating monocytes in inflamed tissues. In contrast, the
number of inflammatory DCs that accumulated in LPS-treated
spleens was dramatically reduced (Figure 7F) and they also
displayed a lower expression of the costimulatory molecules
CD80 and CD86 (Figure S7C). Altogether these results suggest
that Csf-1r signaling, but not Csf-2r, may be critical for the
differentiation of inflammatory DCs in vivo.
DISCUSSION
Csf-2 is a critical cytokine for the differentiation of monocytes
and hematopoietic progenitors into DCs in vitro in mice and
men (Caux et al., 1996; Inaba et al., 1992; Sallusto and Lanza-
vecchia, 1994). However, the exact role of Csf-2 in DC differen-
tiation in vivo has remained an outstanding question in DC
biology since the surprising discovery that Csf2rb/ and
Csf2/mice do not have impaired DC development in lymphoid
organs (Vremec et al., 1997).
In this study we revisited the role of Csf-2 in DC differentiation
in vivo. With mutant and mixed BM chimeric mice, we found
that Csf-2 was absolutely critical for the homeostasis of non-
lymphoid tissue DCs. Deletion of Csf-2, Csf-2rb, or both Csf-
2rb and Csf-2rb2 profoundly affected the homeostasis of
CD103+ and CD11b+ DCs in the lung, skin, and lamina propria,
establishing that Csf-2 and not IL-3 was required for normal DC
homeostasis. These results extend previous results from our
laboratory showing that Csf-2r controls lamina propria DC
homeostasis (Bogunovic et al., 2009) and more recent results
showing that the formation or maintenance of dermal CD103+
DCs is dependent on Csf-2 (King et al., 2010). They are also
consistent with the reported role for Csf-2 in the in vitro differ-
entiation of CD103+ DCs from BM precursors (Sathe et al.,
2011).
CD11b+ DCs as currently defined in nonlymphoid tissues are
heterogeneous and probably contain a contaminating macro-
phage population that also expresses MHCII and CD11c in the
steady state, as recently described in the gut (Bogunovic
et al., 2009; Schulz et al., 2009; Varol et al., 2009). However,
the lack of markers to accurately distinguish DCs from macro-
phages among MHCII+CD11c+CD11b+ cells in tissues other
than the lamina propria (Hashimoto et al., 2011b) dilutes poten-
tial defects induced by the lack of Csf-2r and may explain the
partial reduction of tissue-resident CD11b+ DCs compared to
CD103+ DCs.Importantly, Csf2rb/Csf2rb2/ mice and Csf2rb/
Csf2rb2/ BM chimeric mice were unable to mount antigen-
specific CD8+ effector T cells in the lung and the lung-draining
LNs upon immunization with particulate antigens. These results
are probably due to the strong reduction of lung CD103+ DCs
that aremost potent in inducing the cross-presentation of partic-
ulate antigens to CD8+ T cells (Hildner et al., 2008). In addition, it
was recently shown that Csf-2 controls DC cross-presentation
and cross-priming function in vitro (Sathe et al., 2011). Csf-2-
transduced tumor cells have been used to generate antitumor
CD8+ T cell immunity with some clinical success. The mecha-
nisms that control the clinical potency of this vaccine are not
clearly established but it is critical to examine whether these
vaccines improve antitumor immunity, partly through their
ability to promote the survival and/or the cross-presenting func-
tion of human equivalent CD103+ DCs (Bachem et al., 2010;
Crozat et al., 2010; Jongbloed et al., 2010; Poulin et al., 2010).
Our data also revealed that Csf-2 was produced by both
hematopoietic and stromal cells in nonlymphoid tissues in the
steady state and promoted the survival of tissue CD103+ and
CD11b+ DCs by blocking the mitochondrial apoptosis pathway.
In contrast, Csf-2 was expressed at low levels in lymphoid
organs, and absence of Csf-2 or Csf-2r did not affect lymphoid
tissue-resident DC homeostasis, which is consistent with prior
data (Vremec et al., 1997). These results probably reflect the
nonredundant role of Csf-2 in promoting DC survival in nonlym-
phoid tissue environment. In contrast, Csf-2may be redundant in
lymphoid organs, which harbor several hematopoietic cytokines
such as Flt3L known to promote tissue DC homeostasis in vivo.
Inflammatory DCs are absent from normal tissues and accu-
mulate only upon tissue injury. The exact mechanisms that
control the development of inflammatory DCs remain to be
defined but it is clear that inflammatory DCs derive from circu-
lating bone marrow-derived precursors that probably include
circulating Ly6Chi monocytes (Domı´nguez and Ardavı´n, 2010).
The initial reports showing that Csf-2 is increased in the
serum and lymphoid tissues of infected animals (Hamilton,
2008) led to the suggestion that Csf-2 controls the differen-
tiation of inflammatory DCs (Shortman and Naik, 2007). Our
results, however, do not support a critical role for Csf-2 in
the differentiation of inflammatory DCs in acute models of
inflammation. By using four different acute infection models,
we found that Csf2rb/Csf2rb2/ DCs were phenotypically
identical to and as potent as WT DCs at producing TNF-a and
iNOS. Importantly, Csf2rb/Csf2rb2/ inflammatory DCs that
arise in L. monocytogenes-infected spleens were as efficient
as WT DCs at controlling the initial L. monocytogenes load of
infected animals.
Because inflammatory DCs are thought to differentiate mainly
from circulating Ly6Chi monocytes, we also examined whether
adoptively transferred Csf2rb/Csf2rb2/ Ly6Chi monocytes
can differentiate into DCs in vivo. Consistent with the data
obtained in Csf2rb/Csf2rb2/ mice, adoptively transferred
Csf2rb/Csf2rb2/ monocytes differentiated as efficiently as
did WT monocytes into inflammatory DCs in influenza virus-
infected lungs.
In contrast, Csf-1r blockade either through genetic or pharma-
cological means strongly impaired the accumulation of inflam-
matory DCs in influenza virus-infected lungs and in LPS-treatedImmunity 36, 1031–1046, June 29, 2012 ª2012 Elsevier Inc. 1041
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Figure 7. Csf-1r Signaling Controls the Development of Inflammatory DCs
(A) Histogram depicts CD115 expression of splenic inflammatory DCs isolated from LPS-treated WT mice. Dashed gray line, isotype control; solid black line,
CD115 antibody.
(B) Lungs isolated from uninfected and influenza-infected WT mice were analyzed for Csf-1 and Csf-2 by ELISA (n = 3).
(C–F) Rosa26CreER+ (Cre+) 3 Csf1rfl/fl and Rosa26CreER (Cre) 3 Csf1rfl/fl control mice were treated with tamoxifen (C, D) and WT mice were injected with
Csf-1r antibody (aCsf-1r) (E, F). Seven days after treatment with tamoxifen or aCsf-1r, mice were injected i.v. with LPS.
(C and E) Dot plots display the percentage of SSCloCD11b+Ly6C+Csf-1r (CD115)+ F4/80+ circulating monocytes prior to LPS injection.
(D–F) Dot plots show the percentage of splenic monocytes (R1) (DAPILy6GCD11b+Ly6C+F4/80+). R2 represents MHCII+CD11c+ DCs among gated R1 spleen
monocytes. Graphs display the mean percentage and absolute cell number of spleen monocytes (R1) and inflammatory DC (R2) from combined experiments ±
SEM on day 1 after LPS injection (n = 3 for controls [ctrl., no LPS], n = 6 for LPS-treated groups).
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GM-CSF Controls Tissue DC Homeostasisspleens, suggesting that Csf-1r signaling may promote the
differentiation of monocytes into inflammatory DCs during
acute tissue injuries. These results may help explain prior
data showing that absence of Csf-1 alters the induction of
L. monocytogenes immunity in vivo (Guleria and Pollard, 2001),
although the exact role of Csf-1r in regulating the function
of monocyte-derived DCs remains to be examined in detail.
These results also extend prior results showing that Csf-1r
controls the differentiation of specific DC subsets such as
epidermal LCs and kidney, lung, and gut CD11b+ DCs (Bogu-
novic et al., 2009; Ginhoux et al., 2009; Hashimoto et al.,
2011b). The exact role of Csf-1 in inflammatory DC homeostasis
is currently being examined in the laboratory and may include
a role in the differentiation, proliferation, and survival of DCs
as shown for macrophages (Yu et al., 2008).
In sum, our results reveal that in contrast to the current dogma
that suggests that Csf-2 mainly controls the development of
inflammatory DCs in vivo, Csf-2 is a steady-state cytokine that
controls the induction of CD8+ T cell immunity to particulate
antigens through the regulation of nonlymphoid tissue-resident
DC survival and homeostasis. These results also reveal a role
for Csf-1r in the differentiation of inflammatory DCs and provide
a rationale for the development of clinical strategies using
Csf-1r ligands to enhance innate antimicrobial immunity.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (CD45.2) mice, C57BL/6 (CD45.1) mice, B6.129S1-Csf-2rb2tm1Cgb
Csf-2rbtm1Clsc/J (Csf2rb/Csf2rb2/) mice, B6;129-Gt(ROSA)26Sortm1
(Rosa26-CreER) mice, and OVA-TcR tg mice (TcraTcrb, OT-I) mice were
purchased from the Jackson Laboratory. Csf2/ mice were provided by
M. Manz (University Hospital, Zurich, Switzerland). B6.129S1-Csf2rbtm1Cgb/J
(Csf2rb/) mice were provided by B. Becher (University Zu¨rich). Ccr2/
mice were maintained in our animal facility (Boring et al., 1997). Csf1rfl/fl
mice were provided by J. Pollard (Li et al., 2006) (Albert Einstein, New York,
NY). All animal procedures performed in this study were approved by the
Institutional Animal Care and Use Committee (IACUC) of Mount Sinai School
of Medicine.
Bone Marrow Chimeras
Bone marrow chimeras were generated as described previously (Ginhoux
et al., 2009). In brief, CD45.2+ WT mice were lethally irradiated (23 550
rad, 3 hr apart by a Caesium source) and reconstituted with 5 3 106 BM
cells of a 1:1 mixture of CD45.1+ WT and CD45.2+ WT or CD45.1+ WT and
CD45.2+Csf2rb/Csf2rb2/ or CD45.2+Csf2rb/ BM cells or with 5 3 106
CD45.1+ WT or CD45.2+Csf2rb/Csf2rb2/ BM cells.
Cell Suspension Preparations
Cell suspensions were prepared as previously described (Ginhoux et al., 2009;
Bogunovic et al., 2009) and analyzed by flow cytometry.
Flow Cytometry
Flow cytometry was performedwith an LSR II (Becton Dickinson) and analyzed
with FlowJo software (Tree Star). Fluorochrome- or biotin-conjugated mono-
clonal antibodies (mAbs) specific for mouse MHC class II I-A/I-E (clone M5/
114.15.2), CD11b (clone M1/70), CD11c (clone N418), CD45 (clone 30-F11),
CD45.1 (clone A20), CD45.2 (clone 104), CD115 (clone AFS98), Gr-1Ly6C/G(G) Cre+3 Csf1rfl/fl and Cre–3 Csf1rfl/fl mice were treated with tamoxifen 14 days
and absolute cell number of lung inflammatory DCs (DAPI–CD45+Siglec-F–Ly6G–C
for influenza virus-infected mice).
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, unpaired). See also Figure S7(clone RB6-8C5), Ly6C (clone AL-21), Ly6G (clone 1A8), CD103 (clone 2E7),
CD8a (clone 53-6.7), CD24 (clone M1/69), Mac-3 (clone M3/84), Sirpa
(clone P84), Flt3 (Flk2) (clone A2F10), CD64 (X54-5/7.1), CD3 (145-2C11),
B220 (clone RA3-6B2), TER-119 (TER-119), CD131 (clone JORO50), active
Caspase-3 Ab (C92-605), and TNF-a (cloneMP6-XT22) and the corresponding
isotype controls and the secondary reagents were purchased either from BD
Biosciences or eBioscience. CD123 mAb (clone 5B11) and CD125 mAb
(clone T21) were purchased fromBiolegend. F4/80 (A3-1) mAbwas purchased
from Serotec. Langerin Ab (clone E-17), donkey-anti-goat IgG-PE, and INOS
Ab (clone M-19) were purchased from Santa Cruz. For intracellular TNF-a
and iNOS staining, cells were incubated in vitro with brefeldin A for 4 hr at
37C prior to intracellular staining according to the manufacturer’s protocol.
For Annexin-V staining (BD Biosciences), cells were stained with Annexin-V
according to the manufacturer’s protocol.
Gene Expression Profile
Single-cell suspensions of lymphoid and nonlymphoid tissues were prepared
as described above. DCs were sorted on an ARIA sorter (BD). Microarray
Affymetrix gene chip analysis of sorted monocytes, DC populations, and DC
precursors were performed in collaboration with the Immunological Genome
Project (Immgen).
Infections and Immunizations
Listeria monocytogenes
Mice were immunized i.v. with 2 3 104 CFU of L. monocytogenes 104035. On
days 3 and 7 after infection, spleens and livers were removed and bacteria
CFU was determined by plating serial dilutions of homogenized tissues on
brain-heart infusion agar plates.
Influenza Virus
Influenza viruses (influenza strain A/Puerto Rico/8/34 (PR8) and influenza strain
A/WSN/33 carrying chicken OVA peptide 257–264 SIINFEKL in the stalk region
of neuraminidase (WSN:OTI) were grown either in 9-day-old embryonated
eggs or in MDCK cells. Mice were infected i.n. with 104–107 PFU virus.
Streptococcus pneumoniae
Mice were inoculated i.n. with 106 CFU S. pneumoniae serotype 3 (ATCC
6303).
Lipopolysaccharide
Mice were injected i.v. with 20 mg of lipopolysaccharide (LPS) from Escherichia
coli 0111:B4 (Sigma).
Salmonella Typhimurium
Infection with S. Typhimurium was described previously (Bogunovic et al.,
2009). Mice were pretreated with 20 mg of streptomycin and 24 hr later, orally
infected with 5 3 107 CFU of streptomycin-resistant WT S. Typhimurium.
Experimental Autoimmune Encephalitis
Mice were immunized s.c. in the lateral abdomen with 200 mg MOG35–55 in
CFA, and 200 ng pertussis toxin was administered i.p. on day 0 and day 2.
Monocyte Transfer
Ly6Chi monocytes were isolated as described previously (Ginhoux et al.,
2006). In brief, monocytes were enriched with CD115-Biotin antibody and
anti-Biotin microbeads (Miltenyi) and positively sorted by AutoMACS
(Miltenyi). Subsequently, enriched monocytes were sorted (DAPICD3
CD19Ly6GMHCIICD11cCD11b+Ly6C+F4/80+CD115+) with an ARIA
Sorter (BD). A 1:1 mixture of 6 3 106 WT (CD45.1) and 6 3 106 Csf2rb/
Csf2rb2/ (CD45.2) monocytes was transferred into influenza-infected
recipient mice.
Enzyme-Linked Immunosorbent Assay
Tissue samples were homogenized and lysed in lysing buffer (50 mM Tris,
5mMEDTA, 150mMNaCl, 1%NP40) containing proteinase inhibitors (Roche)
for 30 min on ice. Protein concentrations were determined with a BCA proteinprior to being infected i.n. with influenza virus. Dot plots show the percentage
D11b+F4/80+) 3 days after virus infection (n = 2 for control [not infected], nR 4
.
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GM-CSF Controls Tissue DC Homeostasisassay kit (Pierce). ELISA for Csf-2 (eBioscence) and M-CSF (R&D) were
performed according to the manufacturer’s instructions.
Blocking Csf-1r Signaling In Vivo
Csf-1r mAb (clone AFS98) was purified from culture supernatant of AFS98
hybridoma (gift from S. Nishimura, New York) as previously described (Hashi-
moto et al., 2011a). Mice were injected i.p. at doses of 2 mg/mouse on day
0 and 1 mg/mouse on day 2.
Rosa26-CreER 3 Csf1rfl/fl mice were injected i.p. with 3.5 mg tamoxifen
(Sigma T5648) dissolved in corn oil (Sigma) as previously described (Ginhoux
et al., 2010).
Lung Immunization with OVA-Coated Beads
Mice were immunized with 50 ml of 1 mm latex beads (Polysciences) covalently
coated with OVA (Sigma) according to the manufacturer’s instructions and
mixed with 10 mg of poly(I:C) prior to i.t. injection. For DC-OT-I T cell cultures,
DC subsets were sorted from the lungs (3 hr postinjection) and lung-draining
LN (24 and 72 hr postinjection) on an ARIA sorter (BD) and 10 3 103 DCs
were cocultured with 100 3 103 OT-I CD8+ T cells labeled with 5 mM CFSE
(Molecular Probes).
Mitogreen and Anticleaved Caspase-3 Staining
DCs were sorted on an ARIA sorter (BD) and stained with 0.1 mM Mitogreen
(Invitrogen) for 30 min at 37C or with anticleaved Caspase-3 (Caltag) and
counterstained with DAPI. Images were captured on a Zeiss Axio Imager Z1
with Axiocam MRM and were processed with Axiovision 4.8 Software.
In Vitro DC Culture
DCs were sorted as described above and cultured for 24 hr in the presence or
absence of GM-CSF (50 ng/ml, Biolegend).
Statistical Analysis
Mean values, SEM values, and Student’s t test (unpaired) were calculated with
Prism (GraphPad software). *p < 0.05, **p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
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